Search

Your search keyword '"Bacigalupo, Andrea"' showing total 14 results
Start Over Author "Bacigalupo, Andrea" Journal annals of hematology
14 results on '"Bacigalupo, Andrea"'

2. Acute erythroid leukemia with TP53 mutation and BCR/ABL1: challenges in classification and management

Author

Marra, John Donald, primary, Frioni, Filippo, additional, Minnella, Gessica, additional, Rossi, Monica, additional, Malara, Tanja, additional, Bellesi, Silvia, additional, Maiolo, Elena, additional, Orteschi, Daniela, additional, Galli, Eugenio, additional, Bacigalupo, Andrea, additional, Pagano, Livio, additional, Sica, Simona, additional, Zini, Gina, additional, and Chiusolo, Patrizia, additional

Published
2023
Full Text
View/download PDF

6. Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemia

Author

De Astis, Enrico, Clavio, Marino, Raiola, Anna Maria, Ghiso, Anna, Guolo, Fabio, Minetto, Paola, Galaverna, Federica, Miglino, Maurizio, Di Grazia, Carmen, Ballerini, Filippo, Marani, Carlo, Pastori, Giordana, Mitscheunig, Laura, Cruciani, Fabio, Lovera, Davide, Varaldo, Riccardo, Ghiggi, Chiara, Lemoli, Roberto Massimo, Bacigalupo, Andrea, and Gobbi, Marco

Published
2014
Full Text
View/download PDF

10. Treatment of primary plasma cell leukemia with high doses of cyclophosphamide, bortezomib, and dexamethasone followed by double autologous HSCT

Author

Pagano, Livio, primary, Maraglino, Alessio Maria Edoardo, additional, Fianchi, Luana, additional, Criscuolo, Marianna, additional, Rossi, Elena, additional, Za, Tommaso, additional, Chiusolo, Patrizia, additional, Bonanni, Matteo, additional, Dragonetti, Giulia, additional, Bacigalupo, Andrea, additional, Sica, Simona, additional, and De Stefano, Valerio, additional

Published
2019
Full Text
View/download PDF

11. Epidemiology of viral respiratory tract infections in an outpatient haematology facility

Author

Mikulska, Małgorzata, primary, Del Bono, Valerio, additional, Gandolfo, Nemo, additional, Dini, Simone, additional, Dominietto, Alida, additional, Di Grazia, Carmen, additional, Bregante, Stefania, additional, Varaldo, Riccardo, additional, Orsi, Andrea, additional, Ansaldi, Filippo, additional, Bacigalupo, Andrea, additional, and Viscoli, Claudio, additional

Published
2013
Full Text
View/download PDF

12. CTLA-4 +49A>G polymorphism of recipients of HLA-matched sibling allogeneic stem cell transplantation is associated with survival and relapse incidence

Author

Piccioli, Patrizia, primary, Balbi, Giuseppe, additional, Serra, Martina, additional, Morabito, Anna, additional, Lamparelli, Teresa, additional, Gobbi, Marco, additional, Laurent, Stefania, additional, Dozin, Beatrice, additional, Bruzzi, Paolo, additional, Ferraris, Anna Maria, additional, Bacigalupo, Andrea, additional, Notaro, Rosario, additional, and Pistillo, Maria Pia, additional

Published
2009
Full Text
View/download PDF

13. Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemia.

Author

Astis, Enrico, Clavio, Marino, Raiola, Anna, Ghiso, Anna, Guolo, Fabio, Minetto, Paola, Galaverna, Federica, Miglino, Maurizio, Grazia, Carmen, Ballerini, Filippo, Marani, Carlo, Pastori, Giordana, Mitscheunig, Laura, Cruciani, Fabio, Lovera, Davide, Varaldo, Riccardo, Ghiggi, Chiara, Lemoli, Roberto, Bacigalupo, Andrea, and Gobbi, Marco

Subjects
CANCER relapse, ACUTE leukemia, LIPOSOMES, DAUNOMYCIN, FLUDARABINE, CYTARABINE, STEM cell transplantation, LEUKEMIA treatment, THERAPEUTICS, CANCER treatment
Abstract

Therapeutic options for patients with relapsed or refractory acute leukemia are still undefined and often unsatisfactory. We report the outcome of 79 patients with relapsed-refractory acute leukemia treated with fludarabine, cytarabine, and liposomal daunorubicin (FLAD regimen) followed by hematopoietic stem cell transplantation (HSCT), when clinically indicated, between May 2000 and January 2013. Forty-one patients had acute myeloid leukemia (AML), and 38 had acute lymphoblastic leukemia (ALL). Two patients with myeloid blast crises of CML and three with lymphoid blast crises were included in the AML and ALL subgroups, respectively. Median age was 48 years (range 13-77). FLAD was well tolerated with negligible, nonhematological toxicity. Six patients (7.5 %) died before response evaluation. Forty-seven patients achieved hematologic complete response (CR). Complete remission rate was 53 and 65 % among AML and ALL patients, respectively. No CR was recorded among 11 refractory AML patients. Twenty-four patients (30 %) underwent HSCT. Nine patients received stem cells from an HLA identical sibling, and 15 from an alternative donor (3 unrelated matched, 12 haploidentical sibling). Median overall survival in AML and ALL patients receiving FLAD therapy was 9 and 8 months, respectively. A 5-year projected OS for patients receiving the whole program (FLAD + HSCT) was 24 % for AML patients (median survival 43 months), 28 % for ALL patients treated in relapse (median survival 15 months), and 0 % for ALL patients treated for refractory disease. In this paper, we show that FLAD seems to be an effective bridge therapy to HSCT for a part of poor prognosis acute leukemia patients. However, prospective studies are needed to confirm our results. [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

14. High dose bolus methylprednisolone for the treatment of acute graft versus host disease

Author

Bacigalupo, Andrea, Lint, Maria T., Frassoni, Francesco, Podesta, Marina, Veneziano, Giovanna, Avanzi, Giorgio, Vitale, Vito, and Marmont, Alberto M.

Abstract

Nineteen patients with acute graft versus host disease (GvHD) following bone marrow transplantation (BMT) were treated with high dose bolus 6-methylprednisolone (BMPr), at the dose of 20 mg/kg/day i.v. for the first 3 days, 10 mg/kg/day i.v. for the following 4 days, and then at doses gradually tapered down to 1 mg/kg/day. All patients except one, who was given preventive BMPr 5 mg/kg/day i.v. on alternate days, were placed on preventive methotrexate therapy after BMT. Sixteen patients were grafted with an HLA matched, and three patients with an HLA mismatched marrow.

Published
1983
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results